Alterity Therapeutics Limited (ATHE) Financial Ratios
24 years of historical data (2002–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.62
↑+92% vs avg
5yr avg: 0.84
30Y Low0.5·High8.0
ROE
↑
-43.2%
↓+30% vs avg
5yr avg: -61.7%
30Y Low-175%·High-15%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ATHE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Alterity Therapeutics Limited currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $85M | $44M | $11M | $11M | $24M | $37M | $18M | $13M | $17M | $20M | $42M |
| Enterprise Value | $61M | $11M | $-1472399 | $-4273935 | $-10228414 | $9M | $9M | $-955544 | $2M | $-1508102 | $14M |
| P/E Ratio → | -5.65 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 21.47 | 8.02 | 2.74 | 2.88 | 4.77 | 8.47 | — | 123.87 | 83.60 | 153.91 | 295.66 |
| P/B Ratio | 1.62 | 1.03 | 0.80 | 0.49 | 0.69 | 1.21 | 1.68 | 0.81 | 1.05 | 0.86 | 1.34 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ATHE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.95 | -0.37 | -1.09 | -2.00 | 2.01 | — | -8.80 | 7.86 | -11.39 | 95.22 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ATHE Profitability
Margins and return-on-capital ratios measuring operating efficiency
Alterity Therapeutics Limited earns an operating margin of -268.0%. Operating margins have expanded from -373.7% to -268.0% over the past 3 years, signaling improving operational efficiency. A negative ROE of -43.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.7% | 97.7% | 94.7% | 92.7% | 92.9% | 91.7% | — | 72.6% | 89.2% | 83.9% | 84.0% |
| Operating Margin | -268.0% | -268.0% | -487.7% | -373.7% | -302.6% | -349.8% | — | -11713.7% | -3862.5% | -5197.9% | -6019.2% |
| Net Profit Margin | -223.4% | -223.4% | -475.8% | -352.5% | -250.7% | -352.8% | — | -11020.8% | -4108.8% | -5696.6% | -5418.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -43.2% | -43.2% | -104.5% | -47.4% | -39.0% | -74.6% | -74.2% | -73.3% | -41.6% | -27.4% | -21.9% |
| ROA | -37.2% | -37.2% | -82.2% | -40.2% | -34.3% | -65.3% | -60.6% | -61.9% | -37.6% | -25.6% | -20.5% |
| ROIC | -204.0% | -204.0% | -343.2% | -273.4% | -726.7% | -598.3% | -441.3% | -635.6% | -439.7% | -225.5% | -184.6% |
| ROCE | -51.7% | -51.7% | -106.6% | -50.1% | -46.9% | -73.8% | -76.6% | -77.8% | -39.1% | -25.0% | -24.4% |
ATHE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $33M exceeds total debt of $155457, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.78 | -0.90 | -0.68 | -0.98 | -0.92 | -0.87 | -0.87 | -0.95 | -0.92 | -0.91 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($33M) exceeds total debt ($155457)
ATHE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Alterity Therapeutics Limited's current ratio of 12.98x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 6.17x to 12.98x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.98 | 12.98 | 3.54 | 6.17 | 7.07 | 10.92 | 4.88 | 5.98 | 7.06 | 15.88 | 14.28 |
| Quick Ratio | 12.98 | 12.98 | 3.54 | 6.17 | 7.07 | 10.92 | 4.67 | 5.79 | 6.96 | 15.72 | 14.17 |
| Cash Ratio | 11.50 | 11.50 | 2.35 | 3.60 | 5.98 | 9.17 | 3.39 | 4.34 | 5.77 | 13.79 | 12.13 |
| Asset Turnover | — | 0.12 | 0.21 | 0.14 | 0.12 | 0.13 | — | 0.01 | 0.01 | 0.01 | 0.00 |
| Inventory Turnover | 0.20 | — | — | — | — | — | 0.20 | 0.05 | 0.08 | 0.09 | 0.09 |
| Days Sales Outstanding | — | 264.25 | 367.03 | 806.07 | 332.65 | 347.06 | — | 16241.01 | 5719.57 | 8368.71 | 12247.34 |
ATHE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Alterity Therapeutics Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $11M | $6M | $4M | $4M | $3M | $1M | $1M | $889819 | $889819 | $889819 |
Peer Comparison
Compare ATHE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ATHEYou | $85M | -5.7 | — | — | 97.7% | -268.0% | -43.2% | -204.0% | — |
 PRTA | $567M | -2.3 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 SAVA | $94M | -3.8 | — | — | — | — | -17.2% | -634.1% | — |
 AVXL | $289M | -5.8 | — | — | — | — | -43.1% | — | — |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 BIIB | $28B | 21.7 | 11.4 | 13.8 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 ARVN | $652M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 21.8 | 14.1 | 18.5 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 24 years · Updated daily
See ATHE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ATHE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ATHE vs PRTA
Side-by-side business, growth, and profitability comparison vs Prothena Corporation plc.
Start ComparisonATHE — Frequently Asked Questions
Quick answers to the most common questions about buying ATHE stock.
What is Alterity Therapeutics Limited's P/E ratio?
Alterity Therapeutics Limited's current P/E ratio is -5.7x. This places it at the 50th percentile of its historical range.
What is Alterity Therapeutics Limited's ROE?
Alterity Therapeutics Limited's return on equity (ROE) is -43.2%. The historical average is -70.8%.
Is ATHE stock overvalued?
Based on historical data, Alterity Therapeutics Limited is trading at a P/E of -5.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Alterity Therapeutics Limited's profit margins?
Alterity Therapeutics Limited has 97.7% gross margin and -268.0% operating margin.